Infectious Diseases

Back to articles

Chronic Hepatitis C: New Interferon Formulation Under FDA Review

KEY POINT

New hope in the form of pharmacotherapy will soon be available for patients with chronic hepatitis C, if FDA endorses recently published clinical data as evidence of safety and effectiveness. Expected to be approved by mid- 2001 is peginterferon alfa-2a (Pegasys—Roche), which has a 40-kilodalton branched-chain polyethylene glycol (PEG) moiety covalently attached to interferon alfa-2a.

SOURCES

Zeuzem S et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666–72.

Heathcote EJ et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–80.

Schafer DF, Sorrell MF. Conquering hepatitis C, step by step [editorial]. N Engl J Med. 2000;343:1723–4.